A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Completed · Phase 3 · NCT06010004
Conditions: Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $396
- U.S. investigators named
- 4
- Sites paid
- 1
- Planned or actual enrollment
- 401
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug)
- Dates
- Started 2023-09-28; completion 2025-06-05
- Results posted
- Yes
The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication. This study includes 3 periods as follows: * screening and lead-in period: up to 4 weeks * treatment period: 52 weeks, including 20 weeks of dose escalation, and * safety follow-up period: 2 weeks.
From ClinicalTrials.gov, last updated 2026-06-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $396 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anirudh R. Nandan Student in an Organized Health Care Education/Training Program · San Francisco, CA
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Alejandro Duran Crane, MD Internal Medicine · Cleveland, OH
- Medhat Farwati, MD Student in an Organized Health Care Education/Training Program · Cleveland, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.